More good news for SANUWAVE Health, Inc. (OTCQB: SNWV). This morning, following its news Wednesday of a deal with DocShop Pro, SNWV announced entering into an agreement with Labb Solutions to be the exclusive multinational distributor of the company’s dermaPACE and UltraMIST energy-base medical systems in Turkey, Georgia, Azerbaijan, Belarus, and Kazakhstan. SANUWAVE added that the first ten dermaPACE systems have been ordered and shipped to Turkey.
The deal accelerates SNWV’s international expansion strategy and will now capitalize on Labb Solutions’ leadership position in Turkey and select countries from Eastern Europe and the Middle East for the distribution of innovative medical technologies. The deal with Labb is a second step forward in less than a week for SANUWAVE’s “Energy First” adoption and commercialization program.
Commenting on the most recent agreement, Anar Aliyev, Director of Labb Solutions, said, “We are extremely excited to partner with SANUWAVE Health to bring the innovative dermaPACE and UltraMIST Systems that use energy transfer therapies to physicians and wound care patients in Turkey and parts of the Middle East and Eastern Europe. There is a tremendous opportunity to impact the lives of patients and reduce the cost burden of chronic and acute wounds on the private and public healthcare systems.”
dermaPACE and UltraMIST Drive Value
SANUWAVE is expected to seize upon massive opportunities in 2021. Moreover, analysts at Lake Street Capital are bullish, expecting revenues to reach $25 million this year, which would be record-setting. Two innovative products will lead the way.
The first is its dermaPACE® System, a novel medical system based on shockwave technology, which has been used for nearly 30 years in lithotripsy procedures (destruction of kidney stones) and later in orthopedic treatments. These early lithotripsy and orthopedic devices provided the earliest evidence that there was an effect on wound healing. Pulsed Acoustic Cellular Expression (PACE®) Technology was an advance to that technology and the dermaPACE® System is the first to utilize PACE-specific proprietary protocols for wound treatment.
Used and administered by medical professionals, the dermaPACE® System is FDA cleared for the treatment of diabetic foot ulcers (DFU) and it is the first and only system based on focused electrohydraulic shockwave principle cleared by the FDA for such indication. Moreover, to penetrate international markets, the dermaPACE® System is CE Marked in Europe for advanced wound care indications and in Canada carries a Health Canada Medical Device class II License.
Better still, the dermaPACE® System is currently licensed or approved for advanced wound care indications in Brazil, Mexico and dozens of countries and regions around the world. Thus, SNWV’s multi-continent international expansion plans are expected to continue throughout 2021. Better yet, the two systems could soon position SNWV to compete well against even established international players like Johnson & Johnson (JNJ) and 3M Companies healthcare products (MMM), both of whom may lack a comprehensive from wound-to-closure treatment technology. SANUWAVE does.
UltraMIST® System Acquisition Is A Game Changer
Complementing its dermaPACE System is UltraMIST®, a device that through a fluid mist, provides a low-frequency, non-contact, and pain free ultrasound energy deep inside the wound bed that promotes healing from within. The system works by producing ultrasound acoustic waves that promote healing by reducing inflammation and bacteria in the wound bed, while also increasing the growth of new blood vessels to the area.
Like dermaPACE, the UltraMIST® System treatment must be administered by a healthcare professional and has been cleared by the U.S. Food and Drug Administration (FDA) for the promotion of wound healing through wound cleansing and maintenance debridement combined with ultrasound energy deposited inside the wound that stimulated tissue regeneration. Notably, the UltraMIST® System has been used in thousands of patients for more than a decade and, like dermaPACE, is positioned to expand its international markets presence by leveraging its CE Mark in Europe.
Robust 2021 Expectations
SANUWAVE has been earning investor attention ahead of the expected filing of its 10-K this month. Perhaps more importantly, guidance for the remainder of the year could act as a catalyst to push prices toward substantially higher analyst price targets. Undoubtedly, the two deals announced this week could add momentum to what is already expected to be a record-breaking year for revenues.
Better still, the agreements could be the first of many to advance the stock nearer to analyst targets of $0.34, representing a potential increase of nearly 79% from current levels.
Disclaimers: Hawk Point Media is responsible for the production and distribution of this content. Hawk Point Media is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by Hawk Point Media is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall Hawk Point Media be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by Hawk Point Media, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Hawk Point Media was compensated by wire transfer to produce research, video, email, newsletters, and editorial commentary for SANUWAVE Health. Please click HERE for full disclosures and additional disclaimers. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. Hawk Point Media strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. o